血液学の最新論文（2019年4月前半リリース分）New reports on Hematology
Leukemia
- Blood Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. 2019 Apr 9. pii: blood.2019000120. doi: 10.1182/blood.2019000120. Shanmuganathan N, Braley JA, Yong AS, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S
- Blood Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690. Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, Takei T, Kobayashi A, Ito M, Isobe M, Konuma T, Kato S, Kasajima R, Wada Y, Nagamura-Inoue T, Yamaguchi R, Takahashi S, Imoto S, Miyano S, Tojo A
- Blood ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Blood. 2019 Apr 1. pii: blood-2019-01-896233. doi: 10.1182/blood-2019-01-896233. Douglas SPM, Siipola P, Kovanen P, Pyörälä M, Kakko S, Savolainen ER, Salmenniemi U, Orte K, Kytölä S, Pitkänen E, Porkka K, Kilpivaara O, Wartiovaara-Kautto U
- Blood Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. 133(15):1630-1643 Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F
- Blood Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. 133(15):1652-1663 Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ
- Blood Should young adults with ALL be treated as children? 133(14):1519-1520 Dombret H, Boissel N
- Blood Ponatinib and platelets a conflict in CML. 133(14):1520-1521 Guilhot F
- Blood A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. 133(14):1548-1559 Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA
- Br J Haematol Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia – an updated meta-analysis. Br J Haematol. 2019 Apr 13. doi: 10.1111/bjh.15901. Vidal L, Gurion R, Shargian L, Dreyling M, Gafter-Gvili A
- Br J Haematol Reinforcing osteopontin as a marker of central nervous system relapse in paediatric B-cell acute lymphoblastic leukaemia: SPP1 splice variant 3 in the spotlight. Br J Haematol. 2019 Apr 13. doi: 10.1111/bjh.15917. Santoro JC, Bastos ACSF, Gimba ERP, Emerenciano M
- Br J Haematol Anthropometric factors and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis. Br J Haematol. 2019 Apr 11. doi: 10.1111/bjh.15904. Teras LR, Patel AV, Carter BD, Rees-Punia E, McCullough ML, Gapstur SM
- Br J Haematol Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. Br J Haematol. 2019 Apr 9. doi: 10.1111/bjh.15916. Folta A, Culen M, Jeziskova I, Herudkova Z, Tom N, Hlubinkova T, Janeckova V, Durinikova A, Vydra J, Semerad L, Dvorakova D, Remesova H, Cerovska E, Cetkovsky P, Jindra P, Szotkowski T, Zak P, Mayer J, Racil Z
- Br J Haematol Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol. 2019 Apr 7. doi: 10.1111/bjh.15911. Gohil SH, Evans R, Harasser M, El-Kholy M, Paredes-Moscosso SR, Della Peruta M, Nathwani AC
- Br J Haematol Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol. 2019 Apr 7. doi: 10.1111/bjh.15919. Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP
- Br J Haematol Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. Br J Haematol. 2019 Apr 3. doi: 10.1111/bjh.15918. Man S, Henley P
- Br J Haematol Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15912. Patil N, Went RG
- Br J Haematol Analysis of human papillomavirus infection and leukaemic infiltrate in cutaneous squamous cell carcinoma from patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 Apr 1. doi: 10.1111/bjh.15907. Purcell RV, Hock BD, Gardner J, Goddard L, MacPherson SA, McKenzie JL
- Br J Haematol Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma. 185(2):205 Bataller A, Combalia A, Garcia-Herrera A, Estrach T, Matutes E
- Br J Haematol Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. 185(2):232-239 Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K
- Br J Haematol Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse. 185(2):266-283 Groeneveld-Krentz S, Schroeder MP, Reiter M, Pogodzinski MJ, Pimentel-Gutiérrez HJ, Vagkopoulou R, Hof J, Chen-Santel C, Nebral K, Bradtke J, Türkmen S, Baldus CD, Gattenlöhner S, Haas OA, von Stackelberg A, Karawajew L, Eckert C, Kirschner-Schwabe R
- Br J Haematol Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. 185(2):284-288 Miyamura T, Moritake H, Nakayama H, Tanaka S, Tomizawa D, Shiba N, Saito AM, Tawa A, Shimada A, Iwamoto S, Hayashi Y, Koike T, Horibe K, Manabe A, Mizutani S, Taga T, Adachi S
- Br J Haematol Acute promyelocytic leukaemia with increased basophils. 185(1):7 Zhang J, Li M, He Y
- Br J Haematol Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis. 185(1):65-78 Thurgood LA, Dwyer ES, Lower KM, Chataway TK, Kuss BJ
- Haematologica Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019 Apr 11. pii: haematol.2018.203430. doi: 10.3324/haematol.2018.203430. Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M
- Haematologica Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation. Haematologica. 2019 Apr 11. pii: haematol.2018.205351. doi: 10.3324/haematol.2018.205351. Di Genua C, Norfo R, Rodriguez-Meira A, Wen WX, Drissen R, Booth CAG, Povinelli B, Repapi E, Gray N, Carrelha J, Kettyle LM, Jamieson L, Neo WH, Thongjuea S, Nerlov C, Mead AJ
- Haematologica Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica. 2019 Apr 11. pii: haematol.2018.208835. doi: 10.3324/haematol.2018.208835. Li C, Dong L, Su R, Bi Y, Qing Y, Deng X, Zhou Y, Hu C, Yu M, Huang H, Jiang X, Li X, He X, Zou D, Shen C, Han L, Sun M, Skibbe J, Ferchen K, Qin X, Weng H, Huang H, Song C, Chen J, Jin J
- Haematologica Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia. Haematologica. 2019 Apr 11. pii: haematol.2019.217141. doi: 10.3324/haematol.2019.217141. Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J
- Haematologica Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. 2019 Apr 4. pii: haematol.2018.214429. doi: 10.3324/haematol.2018.214429. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR
- Haematologica Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. Haematologica. 2019 Apr 4. pii: haematol.2018.215236. doi: 10.3324/haematol.2018.215236. Köhnke T, Bücklein V, Rechkemmer S, Schneider S, Rothenberg-Thurley M, Metzeler KH, Sauerland MC, Hiddemann W, Spiekermann K, Subklewe M
- Haematologica Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. 104(4):700-709 Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF
- Haematologica A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. 104(4):717-728 Bernardoni R, Giordani G, Signorino E, Monticelli S, Messa F, Pradotto M, Rosso V, Bracco E, Giangrande A, Perini G, Saglio G, Cilloni D
- Haematologica Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia. 104(4):738-748 Polak R, Bierings MB, van der Leije CS, Sanders MA, Roovers O, Marchante JRM, Boer JM, Cornelissen JJ, Pieters R, den Boer ML, Buitenhuis M
- Haematologica CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. 104(4):749-755 Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD
- Haematologica THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. 104(4):756-765 Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, Eberl W, Berthold F, Bergsträsser E, Gnekow A, Lassay E, Vorwerk P, Lauten M, Sauerbrey A, Rischewski J, Beilken A, Henze G, Korte W, Möricke A; THROMBOTECT Study Investigators
- Haematologica Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment. 104(4):789-796 Brieghel C, Kinalis S, Yde CW, Schmidt AY, Jønson L, Andersen MA, da Cunha-Bang C, Pedersen LB, Geisler CH, Nielsen FC, Niemann CU
- Haematologica First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. 104(4):797-804 Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L
- Haematologica Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia. 104(4):e138-e142 McKeown MR, Johannessen L, Lee E, Fiore C, di Tomaso E
- Haematologica Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. 104(4):e143-e146 Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB
- Haematologica Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. 104(4):e147-e150 Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS
- Haematologica Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. 104(4):e170-e173 Abboud R, Han SY, Duncavage EJ, Cashen AF, Shirai CL, Welch JS, DiPersio JF, Abboud CN
- J Clin Oncol Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. J Clin Oncol. 2019 Apr 12:JCO1801877. doi: 10.1200/JCO.18.01877. Albertsen BK, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Heyman M, Schmiegelow K
- J Clin Oncol Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia. 37(10):763-764 Burke MJ
- J Clin Oncol Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. 37(10):770-779 Pui CH, Rebora P, Schrappe M, Attarbaschi A, Baruchel A, Basso G, Cavé H, Elitzur S, Koh K, Liu HC, Paulsson K, Pieters R, Silverman LB, Stary J, Vora A, Yeoh A, Harrison CJ, Valsecchi MG; Ponte di Legno Childhood ALL Working Group
- J Clin Oncol Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group. 37(10):780-789 McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA
- Lancet Haematol Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses. 6(4):e172-e173 Teachey DT
- Lancet Haematol Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. 6(4):e204-e216 Parker C, Krishnan S, Hamadeh L, Irving JAE, Kuiper RP, Révész T, Hoogerbrugge P, Hancock J, Sutton R, Moorman AV, Saha V
- Lancet Oncol Inotuzumab ozogamicin in acute lymphoblastic leukaemia. Lancet Oncol. 2019 Apr 4. pii: S1470-2045(19)30218-9. doi: 10.1016/S1470-2045(19)30218-9. Gourd E
- Leukemia Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM
- Leukemia SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0456-2. Dong Y, Zhao X, Feng X, Zhou Y, Yan X, Zhang Y, Bu J, Zhan D, Hayashi Y, Zhang Y, Xu Z, Huang R, Wang J, Zhao T, Xiao Z, Ju Z, Andreassen PR, Wang QF, Chen W, Huang G
- Leukemia STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0471-3. Klein K, Witalisz-Siepracka A, Maurer B, Prinz D, Heller G, Leidenfrost N, Prchal-Murphy M, Suske T, Moriggl R, Sexl V
- Leukemia JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility. Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0459-z. Lin M, Nebral K, Gertzen CGW, Ganmore I, Haas OA, Bhatia S, Fischer U, Kuhlen M, Gohlke H, Izraeli S, Trka J, Hu J, Borkhardt A, Hauer J, Auer F
- Leukemia FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis. Leukemia. 2019 Apr 5. doi: 10.1038/s41375-019-0465-1. Hyrenius-Wittsten A, Pilheden M, Falqués-Costa A, Eriksson M, Sturesson H, Schneider P, Wander P, Garcia-Ruiz C, Liu J, Ågerstam H, Hultquist A, Lilljebjörn H, Stam RW, Järås M, Hagström-Andersson AK
- Leukemia Identification of a leukemia-initiating stem cell in human mast cell leukemia. Leukemia. 2019 Apr 5. doi: 10.1038/s41375-019-0460-6. Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P
- Leukemia Blocking ATM-dependent NF-κB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia. Leukemia. 2019 Apr 2. doi: 10.1038/s41375-019-0458-0. Chen YL, Tang C, Zhang MY, Huang WL, Xu Y, Sun HY, Yang F, Song LL, Wang H, Mu LL, Li MH, Zheng WW, Miao Y, Ding LX, Li BS, Shen SH, Liu SL, Li H, Zhu ZQ, Chen HW, Tang ZH, Chen J, Hong DL, Chen HZ, Duan CW, Zhou BS
- Leukemia Data mining for mutation-specific targets in acute myeloid leukemia. 33(4):826-843 Benard B, Gentles AJ, Köhnke T, Majeti R, Thomas D
- Leukemia Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). 33(4):844-862 Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA; European Conference on Infections in Leukemia (ECIL)
- Leukemia Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. 33(4):884-892 Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR
- Leukemia Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. 33(4):893-904 Potter N, Jones L, Blair H, Strehl S, Harrison CJ, Greaves M, Kearney L, Russell LJ
- Leukemia Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. 33(4):905-917 Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH
- Leukemia Transmissible ER stress reconfigures the AML bone marrow compartment. 33(4):918-930 Doron B, Abdelhamed S, Butler JT, Hashmi SK, Horton TM, Kurre P
- Leukemia Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. 33(4):931-944 Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, Khoury JD, Xu B, Huang S, Qiu Y
- Leukemia Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. 33(4):945-956 Blagitko-Dorfs N, Schlosser P, Greve G, Pfeifer D, Meier R, Baude A, Brocks D, Plass C, Lübbert M
- Leukemia Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. 33(4):957-968 Zaborsky N, Gassner FJ, Höpner JP, Schubert M, Hebenstreit D, Stark R, Asslaber D, Steiner M, Geisberger R, Greil R, Egle A
- Leukemia Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. 33(4):969-980 Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A
- Leukemia Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. 33(4):1030-1051 Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P
- Leukemia IDH1-R132 changes vary according to NPM1 and other mutations status in AML. 33(4):1043-1047 Falini B, Spinelli O, Meggendorfer M, Martelli MP, Bigerna B, Ascani S, Stein H, Rambaldi A, Haferlach T
Lymphoma
- Blood PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas. Blood. 2019 Apr 11. pii: blood.2018889931. doi: 10.1182/blood.2018889931. Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martínez JI, Bunting KL, Meier S, Sagaert X, Bagnara D, Guruceaga E, Blanco O, Celay J, Martínez-Baztan A, Casares N, Lasarte JJ, MacCarthy T, Melnick A, Martinez-Climent JA, Roa S
- Blood Acalabrutinib for Mantle Cell Lymphoma. Blood. 2019 Apr 9. pii: blood.2019852368. doi: 10.1182/blood.2019852368. Witzig TE, Inwards D
- Blood Chronic CD30-signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. Blood. 2019 Apr 8. pii: blood.2018880138. doi: 10.1182/blood.2018880138. Sperling SA, Fiedler P, Lechner M, Pollithy A, Ehrenberg S, Schiefer AI, Kenner L, Feuchtinger A, Kühn R, Swinerd G, Schmidt-Supprian M, Strobl LJ, Zimber-Strobl U
- Blood PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF
- Blood Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. 133(15):1664-1676 Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J
- Blood How I treat early-relapsing follicular lymphoma. 133(14):1540-1547 Casulo C, Barr PM
- Br J Haematol Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15889. Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, Gordon L, Karmali R
- Br J Haematol Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma. 185(2):205 Bataller A, Combalia A, Garcia-Herrera A, Estrach T, Matutes E
- Br J Haematol Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. 185(2):240-253 Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK
- Br J Haematol Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. 185(1):25-41 Lees C, Keane C, Gandhi MK, Gunawardana J
- Br J Haematol Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. 185(1):42-52 Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG)
- Br J Haematol Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). 185(1):53-64 Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD
- Br J Haematol Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma. 185(1):79-88 Paczkowska J, Soloch N, Bodnar M, Kiwerska K, Janiszewska J, Vogt J, Domanowska E, Martin-Subero JI, Ammerpohl O, Klapper W, Marszalek A, Siebert R, Giefing M
- Haematologica Liquid biopsy in lymphoma. 104(4):648-652 Rossi D, Spina V, Bruscaggin A, Gaidano G
- Haematologica TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells. 104(4):766-777 Burkhard R, Keller I, Arambasic M, Juskevicius D, Tzankov A, Lundberg P, Bruggmann R, Dirnhofer S, Radpour R, Novak U
- Haematologica Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. 104(4):778-788 Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G, Guerrero-Hernández M, Rodríguez V, Soldini D, Valera A, Moros A, Climent F, González-Barca E, Mercadal S, Arenillas L, Calvo X, Mate JL, Gutiérrez-García G, Casanova I, Mangues R, Sanjuan-Pla A, Bueno C, Menéndez P, Martínez A, Colomer D, Tejedor RE, Teixidó J, Campo E, López-Guillermo A, Borrell JI, Colomo L, Pérez-Galán P, Roué G
- Haematologica Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. 104(4):e151-e153 Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ
- Haematologica Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. 104(4):e154-e157 Evrard SM, Péricart S, Grand D, Amara N, Escudié F, Gilhodes J, Bories P, Traverse-Glehen A, Dubois R, Brousset P, Parrens M, Laurent C
- Haematologica DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers. 104(4):e158-e162 Onaindia A, de Villambrosía SG, Prieto-Torres L, Rodríguez-Pinilla SM, Montes-Moreno S, González-Vela C, Piris MA
- Haematologica Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. 104(4):e163-e166 Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A
- Haematologica Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. 104(4):e174-e177 Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V, Du MQ, Cucco F, Barrans S, Johnson P, Laird SR, Fisher AM, Cullis JO, Graham TA, Okosun J, Fitzgibbon J, Chiecchio L
- Haematologica Comment to “The outcome of peripheral T-cell lymphoma patients failing first-line therapy”. 104(4):e178 Dreger P
- Haematologica The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project. 104(4):e178 Bellei M, Federico M
- J Clin Oncol De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 Apr 2:JCO1900445. doi: 10.1200/JCO.19.00445. Leonard JP
- J Clin Oncol Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP
- J Clin Oncol DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. 37(11):912-922 Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL
- J Clin Oncol Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. 37(11):932-934 Fruman DA
- J Clin Oncol Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. 37(10):823-833 Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma
- Lancet Oncol Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019 Apr 1. pii: S1470-2045(18)30935-5. doi: 10.1016/S1470-2045(18)30935-5. Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM
- Lancet Oncol Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge. Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30021-X. doi: 10.1016/S1470-2045(19)30021-X. Jardin F
- Leukemia Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. Leukemia. 2019 Apr 5. doi: 10.1038/s41375-019-0466-0. Tian XP, Huang WJ, Huang HQ, Liu YH, Wang L, Zhang X, Lin TY, Rao HL, Li M, Liu F, Zhang F, Zhong LY, Liang L, Lan XL, Li J, Liao B, Li ZH, Tang QL, Liang Q, Shao CK, Zhai QL, Cheng RF, Sun Q, Ru K, Gu X, Lin XN, Yi K, Shuang YR, Chen XD, Dong W, Sang W, Sun C, Liu H, Zhu ZG, Rao J, Guo QN, Zhou Y, Meng XL, Zhu Y, Hu CL, Jiang YR, Zhang Y, Gao HY, He WJ, Xia ZJ, Wu CL, Zhang MY, Wang HY, Xie D, Cai QQ
- Leukemia CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019 Apr 2. doi: 10.1038/s41375-019-0463-3. Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D
- Leukemia Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. 33(4):969-980 Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A
- Leukemia Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. 33(4):1047-1051 Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio MC, Matteucci P, Carniti C, Facchetti F, Rossi G, Corradini P
Myeloma
- Blood Myeloma bone disease: from biology findings to treatment approaches. 133(14):1534-1539 Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA
- Blood Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. 133(14):1572-1584 Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ
- Blood Biphenotypic plasma cell myeloma. 133(14):1611 Kurt H, Ferreira KA
- Br J Haematol Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol. 2019 Apr 1. doi: 10.1111/bjh.15888. Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS
- Br J Haematol Substratification of patients with newly diagnosed standard-risk multiple myeloma. 185(2):254-260 Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK
- Br J Haematol Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. 185(1):11-24 Nielsen LK, Abildgaard N, Jarden M, Klausen TW
- Haematologica Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma. Haematologica. 2019 Apr 4. pii: haematol.2018.208280. doi: 10.3324/haematol.2018.208280. Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Ria R, Ricca M, Saltarella I, Naponelli V, Rizzi FMA, Perris R, Corradi A, Vacca A, Bonati A, Lunghi P
- Haematologica Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial. Haematologica. 2019 Apr 4. pii: haematol.2018.205476. doi: 10.3324/haematol.2018.205476. Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P
- Haematologica Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated prediagnostic blood samples. Haematologica. 2019 Apr 4. pii: haematol.2019.216895. doi: 10.3324/haematol.2019.216895. Späth F, Wibom C, Krop EJM, Izarra Santamaria A, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B
- J Clin Oncol Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019 Apr 10:JCO1801006. doi: 10.1200/JCO.18.01006. Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group
- J Clin Oncol Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019 Apr 1:JCO1802096. doi: 10.1200/JCO.18.02096. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T
- Lancet Haematol Myeloma cast nephropathy: the dusk of high cutoff haemodialysis. 6(4):e174-e176 Sallée M, Burtey S
- Lancet Haematol High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. 6(4):e217-e228 Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M
- Lancet Oncol NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. Lancet Oncol. 2019 Apr 10. pii: S1470-2045(19)30222-0. doi: 10.1016/S1470-2045(19)30222-0. Elsada A, Adler AI
- Leukemia Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C
- Leukemia Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019 Apr 8. doi: 10.1038/s41375-019-0467-z. Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D
- Leukemia The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. 33(4):863-883 Harding T, Baughn L, Kumar S, Van Ness B
- Leukemia Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. 33(4):1011-1022 Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, McClure JJ, Champion MM, Chou CJ, Sharik ME, Chesi M, Bergsagel PL, Dolloff NG
SCT
- Blood PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF
- Blood Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690. Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, Takei T, Kobayashi A, Ito M, Isobe M, Konuma T, Kato S, Kasajima R, Wada Y, Nagamura-Inoue T, Yamaguchi R, Takahashi S, Imoto S, Miyano S, Tojo A
- Br J Haematol Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15898. Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K
- Haematologica State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. 104(4):659-668 McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N
- Haematologica Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. 104(4):827-834 Radujkovic A, Dai H, Kordelas L, Beelen D, Rachakonda SP, Müller-Tidow C, Kumar R, Dreger P, Luft T
- Haematologica Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation. 104(4):835-843 Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng GS, Carpenter PA, Balgansuren G, Petersdorf EW, Delaney C, Sandmaier BM, Milano F, Flowers ME
- Haematologica Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. 104(4):e174-e177 Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V, Du MQ, Cucco F, Barrans S, Johnson P, Laird SR, Fisher AM, Cullis JO, Graham TA, Okosun J, Fitzgibbon J, Chiecchio L
- J Clin Oncol Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019 Apr 10:JCO1801006. doi: 10.1200/JCO.18.01006. Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group
- J Clin Oncol Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia. 37(10):763-764 Burke MJ
- J Clin Oncol Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group. 37(10):780-789 McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA
- J Clin Oncol Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. 37(10):823-833 Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma
HSC
- Blood Asrij/OCIAD1 suppresses CSN5-mediated p53 degradation and maintains mouse hematopoietic stem cell quiescence. Blood. 2019 Apr 5. pii: blood.2019000530. doi: 10.1182/blood.2019000530. Sinha S, Dwivedi TR, Yengkhom R, Bheemsetty VA, Abe T, Kiyonari H, VijayRaghavan K, Inamdar MS
- Blood Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690. Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, Takei T, Kobayashi A, Ito M, Isobe M, Konuma T, Kato S, Kasajima R, Wada Y, Nagamura-Inoue T, Yamaguchi R, Takahashi S, Imoto S, Miyano S, Tojo A
- Blood The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination. 133(14):1560-1571 Donaghy R, Han X, Rozenova K, Lv K, Jiang Q, Doepner M, Greenberg RA, Tong W
- Br J Haematol Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15898. Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K
- Haematologica Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation. Haematologica. 2019 Apr 11. pii: haematol.2018.205351. doi: 10.3324/haematol.2018.205351. Di Genua C, Norfo R, Rodriguez-Meira A, Wen WX, Drissen R, Booth CAG, Povinelli B, Repapi E, Gray N, Carrelha J, Kettyle LM, Jamieson L, Neo WH, Thongjuea S, Nerlov C, Mead AJ
- Haematologica Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms. 104(4):639-641 Herlihy N, Harrison CN, McLornan DP
- Haematologica Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. 104(4):844-854 Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE
- J Clin Oncol Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group. 37(10):780-789 McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA
- Lancet Haematol Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019 Apr 10. pii: S2352-3026(19)30021-3. doi: 10.1016/S2352-3026(19)30021-3. Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A
- Leukemia Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis. Leukemia. 2019 Apr 1. doi: 10.1038/s41375-019-0462-4. Mallaney C, Ostrander EL, Celik H, Kramer AC, Martens A, Kothari A, Koh WK, Haussler E, Iwamori N, Gontarz P, Zhang B, Challen GA
Anemia
- Br J Haematol Impaired cellular and humoral immunity is a feature of Diamond-Blackfan anaemia; experience of 107 unselected cases in the United Kingdom. Br J Haematol. 2019 Apr 13. doi: 10.1111/bjh.15915. Iskander D, Roberts I, Rees C, Szydlo R, Alikian M, Neale M, Harrington Y, Kelleher P, Karadimitris A, de la Fuente J
- Br J Haematol High prevalence of altered sudomotor function in homozygous sickle cell patients: influence of age and anaemia. Br J Haematol. 2019 Apr 1. doi: 10.1111/bjh.15892. Affes Z, Lionnet F, Livrozet M, Santin A, Frochot V, Letavernier E, Lefaucheur JP, Haymann JP
- Br J Haematol Potential roles of artificial intelligence learning and faecal immunochemical testing for prioritisation of colonoscopy in anaemia. 185(2):311-316 Ayling RM, Lewis SJ, Cotter F
- Br J Haematol Intravenous iron treatment reduces coagulability in patients with iron deficiency anaemia: a longitudinal study. 185(1):93-101 Nashashibi J, Avraham GR, Schwartz N, Awni Y, Elias M
- Haematologica Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica. 2019 Apr 4. pii: haematol.2018.206540. doi: 10.3324/haematol.2018.206540. Rogers ZR, Nakano TA, Olson TS, Bertuch AA, Wang W, Gillio A, Coates TD, Chawla A, Castillo P, Kurre P, Gamper C, Bennett CM, Joshi S, Geddis AE, Boklan J, Nalepa G, Rothman JA, Huang JN, Kupfer GM, Cada M, Glader B, Walkovich KJ, Thompson AA, Hanna R, Vlachos A, Malsch M, Weller EA, Williams DA, Shimamura A
- Haematologica Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia. 104(4):e127-e130 Thielemans L, Layton DM, Shovlin CL
- J Clin Oncol Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019 Apr 10:JCO1802142. doi: 10.1200/JCO.18.02142. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A
- Lancet Haematol Sickle-cell anaemia-keeping alive Wethers’ legacy. 6(4):e167 The Lancet Haematology
Bone marrow failure
- このキーワードに関連した論文はありません
ITP
- Br J Haematol Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol. 2019 Apr 4. doi: 10.1111/bjh.15890. Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C
- Br J Haematol Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. 185(1):102-106 Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB